Abiopharma

🔍 ERGEN CHARLES W (Executive)

Company: EchoStar CORP (SATS)

Report Date: 2026-06-15

Detailed Transactions and Holdings:

• Holds 0 shares of Class A Common Stock (Direct)
  Date: 2026-06-15 | Code: H | shares_owned_after: 11,140,269.00
• Holds 0 shares of Class A Common Stock (Direct)
  Date: 2026-06-15 | Code: H | nature_of_ownership: I | shares_owned_after: 11,404.00 | Footnotes: F1
• Holds 0 shares of Class A Common Stock (Direct)
  Date: 2026-06-15 | Code: H | nature_of_ownership: I | shares_owned_after: 1,967.00 | Footnotes: F2
• Holds 0 shares of Class A Common Stock (Direct)
  Date: 2026-06-15 | Code: H | nature_of_ownership: I | shares_owned_after: 1,313.00 | Footnotes: F3
• Holds 0 shares of Class A Common Stock (Direct)
  Date: 2026-06-15 | Code: H | nature_of_ownership: I | shares_owned_after: 11,921.00 | Footnotes: F4
• Holds 0 shares of Class A Common Stock (Direct)
  Date: 2026-06-15 | Code: H | nature_of_ownership: I | shares_owned_after: 766,443.00 | Footnotes: F5
• Holds 0 shares of Class A Common Stock (Direct)
  Date: 2026-06-15 | Code: H | nature_of_ownership: I | shares_owned_after: 2,350,696.00 | Footnotes: F6
• Holds 0 shares of Class A Common Stock (Direct)
  Date: 2026-06-15 | Code: H | nature_of_ownership: I | shares_owned_after: 1,551,355.00 | Footnotes: F7
• Sold 4,300,000 shares of Class B Common Stock (Derivative)
  Date: 2026-06-15 | Code: G | equity_swap_involved: 0 | shares_owned_after: 71,914.00 | transaction_form_type: 4 | Footnotes: F8, F9, F8, F8
• Acquired 4,300,000 shares of Class B Common Stock (Derivative)
  Date: 2026-06-15 | Code: G | equity_swap_involved: 0 | shares_owned_after: 4,300,000.00 | transaction_form_type: 4 | Footnotes: F8, F9, F8, F8, F9
• Holds 60,517,502 shares of Class B Common Stock (Derivative)
  Date: 2026-06-15 | Code: H | shares_owned_after: 60,517,502.00 | Footnotes: F8, F8, F8, F6
• Holds 18,561,842 shares of Class B Common Stock (Derivative)
  Date: 2026-06-15 | Code: H | shares_owned_after: 18,561,842.00 | Footnotes: F8, F8, F8, F10
• Holds 16,800,000 shares of Class B Common Stock (Derivative)
  Date: 2026-06-15 | Code: H | shares_owned_after: 16,800,000.00 | Footnotes: F8, F8, F8, F11
• Holds 8,000,000 shares of Class B Common Stock (Derivative)
  Date: 2026-06-15 | Code: H | shares_owned_after: 8,000,000.00 | Footnotes: F8, F8, F8, F12
• Holds 23,097,210 shares of Class B Common Stock (Derivative)
  Date: 2026-06-15 | Code: H | shares_owned_after: 23,097,210.00 | Footnotes: F8, F8, F8, F13

Footnotes:

• F1: By 401(K).
• F2: Held by Mrs. Cantey M. Ergen, Mr. Ergen's spouse.
• F3: Held by Mrs. Ergen in a 401(k) account.
• F4: The shares are owned beneficially by the reporting persons' child. The reporting persons disclaim beneficial ownership of the shares, except to the extent of their pecuniary interest therein.
• F5: The shares are held by a charitable foundation. The reporting persons are officers of the charitable foundation and share voting and dispositive power for the foundation. The reporting persons disclaim beneficial ownership of the shares, except to the extent of their pecuniary interest therein.
• F6: The shares are held by Telluray Holdings, LLC. Mr. Ergen and Mrs. Ergen are the managers of Telluray Holdings, LLC. Mrs. Ergen, as a manager of Telluray Holdings, LLC, has sole voting power over the Class A shares and Class B shares held by Telluray Holdings, LLC, and Mr. Ergen and Mrs. Ergen, as the managers of Telluray Holdings, LLC, share dispositive power over the Class A shares and Class B shares held by Telluray Holdings, LLC. The reporting persons disclaim beneficial ownership of the shares, except to the extent of their pecuniary interest therein.
• F7: These shares are beneficially owned indirectly by Mr. Ergen through nXgen Opportunities, LLC, which controls CONX Corp. The reporting persons disclaim beneficial ownership of the shares except to the extent of their pecuniary interest therein.
• F8: The holder of Class B shares may elect to convert any or all of their Class B shares into an equal number of Class A shares at any time for no additional consideration.
• F9: On June 15, 2026, Mr. Ergen established the Ergen Two-Year June 2026 SATS GRAT (the "June 2026 GRAT") and contributed 4,300,000 Class B shares to the June 2026 GRAT. The June 2026 GRAT may elect to convert any or all of its Class B shares into an equal number of Class A shares at any time for no additional consideration. The June 2026 GRAT is scheduled to expire in accordance with its terms on June 15, 2028. Mrs. Cantey M. Ergen serves as the trustee of such GRAT.
• F10: On July 10, 2024, Mr. Ergen established the Ergen Two-Year July 2024 SATS GRAT (the "2024 July GRAT") and contributed 26,500,000 Class B shares to the 2024 July GRAT. The 2024 July GRAT currently holds 18,561,842 Class B shares. The 2024 July GRAT is scheduled to expire in accordance with its terms on July 10, 2026. Mrs. Cantey M. Ergen serves as the trustee of the 2024 July GRAT.
• F11: On June 26, 2025, Mr. Ergen established the Ergen Two-Year June 2025 SATS GRAT (the "2025 June GRAT") and contributed 16,800,000 Class B shares to the 2025 June GRAT. The 2025 June GRAT is scheduled to expire in accordance with its terms on June 26, 2027. Mrs. Cantey M. Ergen serves as the trustee of the 2025 June GRAT.
• F12: On July 29, 2025, Mr. Ergen established the Ergen Two-Year July 2025 SATS GRAT (the "2025 July GRAT") and contributed 8,000,000 Class B shares to the 2025 July GRAT. The 2025 July GRAT is scheduled to expire in accordance with its terms on July 29, 2027. Mrs. Cantey M. Ergen serves as the trustee of the 2025 July GRAT.
• F13: On May 13, 2026, Mr. Ergen established the Ergen Two-Year May 2025 SATS GRAT (the "2025 May GRAT") and contributed 26,000,000 Class B shares to the 2025 May GRAT. The 2025 May GRAT currently holds 23,097,210 Class B shares. The 2025 May GRAT is scheduled to expire in accordance with its terms on May 13, 2027. Mrs. Cantey M. Ergen serves as the trustee of the 2025 May GRAT.